Davoceticept
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells[1].
Product Specifications
CAS Number
[2307144-64-3]
Product Name Alternative
ALPN-202; CD80 vIgD-Fc
UNSPSC
12352203
Target
CTLA-4
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/davoceticept.html
Purity
99.96
Solubility
10 mM in DMSO
Smiles
[Davoceticept]
Molecular Weight
(77.425 kDa)
References & Citations
[1]Davoceticept. IMGT.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1192870-01 0.02 mg (E-Coli)
Recombinant Haemophilus influenzae Modulator of drug activity B homolog (mdaB)
Ask
View Details MBS1192870-02 0.1 mg (E-Coli)
Recombinant Haemophilus influenzae Modulator of drug activity B homolog (mdaB)
Ask
View Details MBS1192870-03 0.02 mg (Yeast)
Recombinant Haemophilus influenzae Modulator of drug activity B homolog (mdaB)
Ask
View Details MBS1192870-04 0.1 mg (Yeast)
Recombinant Haemophilus influenzae Modulator of drug activity B homolog (mdaB)
Ask
View Details 
MBS1192870-05 0.02 mg (Baculovirus)
Recombinant Haemophilus influenzae Modulator of drug activity B homolog (mdaB)
Ask
View Details MBS1192870-06 0.02 mg (Mammalian-Cell)
Recombinant Haemophilus influenzae Modulator of drug activity B homolog (mdaB)
Ask
View Details